Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Jazz Pharma Plc (JAZZ) NASDAQ

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Jazz Pharma Plc 4TH FLOOR CONNAUGHT HOUSE ONE BURLINGTON ROAD DUBLIN L2 D04

www.jazzpharmaceuticals.com P: 353-1634-7800 F: 353-163-4785

Description:

Jazz Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on identifying, developing and commercializing innovative products to meet unmet medical needs in neurology and psychiatry. Company's goal is to build a broad portfolio of products through a combination of internal development and acquisition/in-licensing activities and to utilize our specialty sales force to promote products in our target markets. They apply novel formulations and drug delivery technologies to known drug compounds, and compounds with the same mechanism of action or similar chemical structure as marketed products, to improve patient care by improving efficacy, reducing adverse side effects or increasing patient compliance relative to existing therapies. Based in Palo Alto, California, the company is committed to working closely with patients, patient advocacy groups and healthcare professionals.

Key Statistics

Overview:

Market Capitalization, $K 7,025,330
Shares Outstanding, K 60,530
Last Quarter Sales, $ 374,180 K
Last Quarter Net Income, $ 87,150 K
% of Insider Shareholders 3.90%
% of Institutional Shareholders 89.21%

Growth:

1-Year Return -4.23%
3-Year Return -24.55%
5-Year Return 151.35%
5-Year Revenue Growth 0.00%
5-Year Earnings Growth 0.00%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings 2.57 on 11/08/16
EPS Growth vs. Prev Qtr 20.00%
Annual EPS, $ 8.10
EPS Growth vs. Prev Year 55.40%
Annual Dividend Rate, $ 0.00
Annual Dividend Yield, % 0.00%
36-Month Beta 1.30

JAZZ Ratios

Ratio
Price/Earnings ttm 14.48
Return on Equity % 20.61
Return on Assets % 13.21
Price/Sales 4.91
Price/Book 4.14
Profit Margin % 24.87
Debt/Equity N/A
Interest Coverage 7.29
Book Value/Share 28.35
Annual Dividend Yield 0.00%
Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.